These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9132558)

  • 1. [A prospective study on nephrotoxicity induced by continuous infusion of high-dose ifosfamide (15/m2)].
    Ferrari S; Zolezzi C; Bacci G; Pieretti F; Iantorno D; Figus E; Pizzoferrato A
    Minerva Pediatr; 1997; 49(1-2):29-37. PubMed ID: 9132558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
    Ferrari S; Zolezzi C; Cesari M; Fasano MC; Lamanna G; Bacci G
    Anticancer Drugs; 1999 Jan; 10(1):25-31. PubMed ID: 10194544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations.
    Canpolat C; Pearson P; Robertson R; Jaffe N
    Med Pediatr Oncol; 1996 Jan; 26(1):36-47. PubMed ID: 7494510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
    Oberlin O; Fawaz O; Rey A; Niaudet P; Ridola V; Orbach D; Bergeron C; Defachelles AS; Gentet JC; Schmitt C; Rubie H; Munzer M; Plantaz D; Deville A; Minard V; Corradini N; Leverger G; de Vathaire F
    J Clin Oncol; 2009 Nov; 27(32):5350-5. PubMed ID: 19826134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumor.
    Raney B; Ensign LG; Foreman J; Khan F; Newton W; Ortega J; Ragab A; Wharam M; Wiener E; Maurer H
    Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):286-95. PubMed ID: 7978043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.
    Stöhr W; Paulides M; Bielack S; Jürgens H; Treuner J; Rossi R; Langer T; Beck JD
    Pediatr Blood Cancer; 2007 Apr; 48(4):447-52. PubMed ID: 16628552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal dysfunctions secondary to ifosfamide treatment in children.
    Tokuc G; Yalçiner A; Kebudi R; Dogan S; Görgün O; Ayan I
    J Exp Clin Cancer Res; 1997 Jun; 16(2):227-30. PubMed ID: 9261752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity.
    Berrak SG; Pearson M; Berberoğlu S; Ilhan IE; Jaffe N
    Pediatr Blood Cancer; 2005 Mar; 44(3):215-9. PubMed ID: 15503294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children.
    Loebstein R; Atanackovic G; Bishai R; Wolpin J; Khattak S; Hashemi G; Gobrial M; Baruchel S; Ito S; Koren G
    J Clin Pharmacol; 1999 May; 39(5):454-61. PubMed ID: 10234592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
    Lanvers-Kaminsky C; Krefeld B; Dinnesen AG; Deuster D; Seifert E; Würthwein G; Jaehde U; Pieck AC; Boos J
    Pediatr Blood Cancer; 2006 Aug; 47(2):183-93. PubMed ID: 16302218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
    Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
    Pediatr Blood Cancer; 2010 Jul; 54(7):983-9. PubMed ID: 20405516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ifosfamide-induced nephrotoxicity].
    Rossi R; Rath B; Ullrich K; Ehrich JH
    Monatsschr Kinderheilkd; 1993 Jul; 141(7):594-601. PubMed ID: 8413339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesna excretion and ifosfamide nephrotoxicity in children.
    Goren MP; Pratt CB; Meyer WH; Wright RK; Dodge RK; Viar MJ
    Cancer Res; 1989 Dec; 49(24 Pt 1):7153-7. PubMed ID: 2510931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
    Skinner R; Cotterill SJ; Stevens MC
    Br J Cancer; 2000 May; 82(10):1636-45. PubMed ID: 10817497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to high-dose ifosfamide in patients with advanced/recurrent Ewing sarcoma.
    Ferrari S; del Prever AB; Palmerini E; Staals E; Berta M; Balladelli A; Picci P; Fagioli F; Bacci G; Vanel D
    Pediatr Blood Cancer; 2009 May; 52(5):581-4. PubMed ID: 19142994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients].
    Baranzelli MC; Pichon F; Gourmel B; N'Guyen M; Deligny N; Demaille MC
    Bull Cancer; 1997 Feb; 84(2):141-6. PubMed ID: 9180836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma].
    Chen LK; Xu GC; Teng XY; Liang Y; Liu JL; Zhou XM
    Ai Zheng; 2002 Aug; 21(8):903-6. PubMed ID: 12478904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas].
    Ishii T; Umeda T; Kitoh M; Tatezaki S; Satoh T
    Gan To Kagaku Ryoho; 1993 Mar; 20(4):509-14. PubMed ID: 8452388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.